Silence Therapeutics stock soars 126% on Merck KGaA acquisition deal
FROM THE WIRE · RTTNEWS.COM
Silence Therapeutics plc (SLN) is up 125.52 percent, gaining $10.90 to $19.58 on Monday. The surge follows a definitive agreement for Merck KGaA, Darmstadt, Germany, to acquire Silence Therapeutics in an all-cash transaction with an enterprise value of $1.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe target stock jumps on the all-cash acquisition agreement, while the impact on the broader market stays limited.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Silence Therapeutics rose 125.52% to $19.58 on Monday.
- 02Merck KGaA, Darmstadt, Germany, signed a definitive agreement to acquire the company.
- 03The transaction is all-cash, with an enterprise value of $1 (text truncated).
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Silence Therapeutics plc19.57 USD+0.05%today +125.52%Positive Merck KGaA144.35 EURMarket closedtoday +0.03%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets